Hikal is currently trading at Rs. 295.00, up by 6.30 points or 2.18% from its previous closing of Rs. 288.70 on the BSE.
The scrip opened at Rs. 291.00 and has touched a high and low of Rs. 304.50 and Rs. 290.00 respectively. So far 1713 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.10 on 9-Sept-2010 and a 52 week low of Rs. 262.00 on 10-Feb-2011.
Last one week high and low of the scrip stood at Rs. 348.00 and Rs. 270.00 respectively. The current market cap of the company is Rs. 484 crore.
The promoters holding in the company stood at 68.82% while Institutions and Non-Institutions held 6.93% and 24.25% respectively.
Credit rating agency, ICRA has assigned BB+ rating to enhanced Rs 149.0 crore Fund based limits (enhanced from Rs 70.0 crore), Rs 197.1 crore Term loans (enhanced from Rs 144.6 crore) and $32 million term loans (enhanced from $25.5 million) of Hikal. The outlook on the long term rating is stable. The rating agency has also assigned A4+ rating to the enhanced Rs 105 crore (earlier Rs 125 crores) fund based limits and Rs 55 crore (enhanced from Rs. 45 crore) non fund based limits of the company.
Though a part of the long term loans of the company is denominated in foreign currency, ICRA’s ratings for the same are on national rating scale, as distinct from an international rating scale.
The rating derives strength from the company’s strong product profile, entrenched relationship with leading Pharma and Agro chemicals companies in the world and strong market position for Gabapentin business.
Hikal provides world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
